IMMUNITYBIO
Live / Applied — Ex parte appeal pending (as of 01 Oct 2025)
What this means for you
Not registered yet, but its 16 Sept 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97594882
- Mark type
- Stylized text
- Filed
- 16 Sept 2022
- Attorney of record
- MICHAEL J MCCUE
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, and treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; biological preparations for medical purposes, namely, vaccines for human use and animal use; low-dose chemotherapies, low dose radiation therapies, and personalized neoepitope-targeted therapies, all of the foregoing in the nature of pharmaceutical preparations for medical use for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases, and cancer; anti-cancer preparations; vaccines; biologics, namely, cell-derived preparations, cell therapies, monoclonal antibodies, cytokines, immune modulators, low-dose chemotherapy, low-dose radiation therapy, antibodies, fusion proteins, peptide and cytokine biologics, vaccines, personalized neoepitope-based therapies, cell therapies, and natural killer cell derived preparations, all of the foregoing in the nature of pharmaceutical preparations for clinical, medicinal, therapeutic, and veterinary purposes for the prevention, diagnosis, and treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; kits for clinical, medicinal, therapeutic, and veterinary purposes comprised of clinical medical reagents, cell cultures media for laboratory use, and related printer user instructions sheets
Owner
- NANTCELL, INC., Culver City, CA, US
Prior registrations
Prosecution history
- 08 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 08 Oct 2025 — ASSIGNED TO LIE
- 01 Oct 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 01 Oct 2025 — EX PARTE APPEAL-INSTITUTED
- 01 Oct 2025 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
- 01 Oct 2025 — EXPARTE APPEAL RECEIVED AT TTAB
- 26 Jun 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 26 Jun 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 01 Apr 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 01 Apr 2025 — FINAL REFUSAL E-MAILED
- 01 Apr 2025 — FINAL REFUSAL WRITTEN
- 05 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Aug 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 Aug 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED